AR005338A1 - Derivados acetidinalquilicos de heterociclos con nitrogeno n-sustituido o sales farmaceuticamente aceptables de los mismos, un procedimiento paraprepararlos, composiciones farmaceuticas que los comprenden, uso de dichos derivados, sales y composiciones, y compuestos utilizables como intermedios - Google Patents
Derivados acetidinalquilicos de heterociclos con nitrogeno n-sustituido o sales farmaceuticamente aceptables de los mismos, un procedimiento paraprepararlos, composiciones farmaceuticas que los comprenden, uso de dichos derivados, sales y composiciones, y compuestos utilizables como intermediosInfo
- Publication number
- AR005338A1 AR005338A1 ARP970100003A ARP970100003A AR005338A1 AR 005338 A1 AR005338 A1 AR 005338A1 AR P970100003 A ARP970100003 A AR P970100003A AR P970100003 A ARP970100003 A AR P970100003A AR 005338 A1 AR005338 A1 AR 005338A1
- Authority
- AR
- Argentina
- Prior art keywords
- cycloalkyl
- salts
- derivatives
- c4alkyl
- aryl
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- -1 N-SUBSTITUTED NITROGEN Chemical class 0.000 title 1
- 239000002131 composite material Substances 0.000 title 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 abstract 1
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrane Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Derivados acetidinalquilicos de heterociclos con nitrógeno N-sustituído de fórmula (I) y las sales farmacéuticamente aceptables de los mismos, en la que Res cicloalquilo C3-C7; arilo o alquilo C1-C4, opcionalmente sustituído con flúor,- COOH,- COOalquilo C1-C4, cicloalquilo C3-C7, adamantilo, arilo o het1,estando el cicloalquilo C3-C7 opcionalmente sustituído con 1 o 2 sustituyentes elegidos cada uno independientemente entre alquilo C1-C4, cicloalquilo C3-C7,alcoxi C1-C4, hidroxi,flúor, fluoroalquilo C1-C4 y fluoroalcoxi CC1-C4; A es CO o SO2; R1 es fenilo, bencilo, naftilo, tienilo, benzotienilo o indolilo,cada uno opcionalmente sustituído con uno o dos sustituyentes elegidos independientemente entre alquilo C1-C4alcixi C1-C4, halo y trifluormetilo; R2es -CO2H,-CONR3R4, -CONR5cicloalquilo C3-C7,- NR3 (alcanoilo C2-C3), -NR3R4, -NR5CONR5R6, (cicloalquilo C3-C7- alquilo C1-C4) R5N-, ( cicloalquilo C3-C7alquilo C1-C4) 2N-,-NR5COCF3, -NR5SO2CF3-,- NR5(SO2alquilo C1- C4),-NR5SO2NR5R6 ,-NR5(aril SO2), -N(aril)(SO2 alquilo C1-C4), OR5, -O(cicloalquilo C3-C7),-SO2NR5R6, het1 un grupo de fórmulas (II) a (IX); X es alquileno C1-C4; X1 es un enlace directo o alquileno C1-C6; m es O, 1 o 2. Dichoscompuestos y salesso n antagonistas de las taquicinas. La invención se refiere además a un procedimiento para prepararlos, a composiciones farmacéuticas que loscomprenden, al uso de dichos derivados, sales y composiciones y a compuestosutilizables como interm edios
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9600235.7A GB9600235D0 (en) | 1996-01-05 | 1996-01-05 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR005338A1 true AR005338A1 (es) | 1999-04-28 |
Family
ID=10786682
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970100003A AR005338A1 (es) | 1996-01-05 | 1997-01-02 | Derivados acetidinalquilicos de heterociclos con nitrogeno n-sustituido o sales farmaceuticamente aceptables de los mismos, un procedimiento paraprepararlos, composiciones farmaceuticas que los comprenden, uso de dichos derivados, sales y composiciones, y compuestos utilizables como intermedios |
| ARP970100004A AR005339A1 (es) | 1996-01-05 | 1997-01-02 | Anticuerpos monoclonales antiidiotipos (ab2) y sus usos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970100004A AR005339A1 (es) | 1996-01-05 | 1997-01-02 | Anticuerpos monoclonales antiidiotipos (ab2) y sus usos |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US6242438B1 (es) |
| EP (1) | EP0871623B1 (es) |
| JP (2) | JP3123611B2 (es) |
| KR (1) | KR100275402B1 (es) |
| AP (1) | AP709A (es) |
| AR (2) | AR005338A1 (es) |
| AT (1) | ATE232526T1 (es) |
| AU (1) | AU708282B2 (es) |
| BG (1) | BG102589A (es) |
| BR (1) | BR9612412A (es) |
| CA (1) | CA2237189C (es) |
| CO (1) | CO4750815A1 (es) |
| CZ (1) | CZ209398A3 (es) |
| DE (1) | DE69626220T2 (es) |
| DK (1) | DK0871623T3 (es) |
| DZ (1) | DZ2155A1 (es) |
| ES (1) | ES2190486T3 (es) |
| GB (1) | GB9600235D0 (es) |
| HR (1) | HRP970006A2 (es) |
| HU (1) | HUP9903590A3 (es) |
| IL (2) | IL124309A (es) |
| IS (1) | IS1876B (es) |
| MA (1) | MA26417A1 (es) |
| NO (1) | NO311838B1 (es) |
| NZ (1) | NZ324712A (es) |
| OA (1) | OA10863A (es) |
| PE (1) | PE29798A1 (es) |
| PL (1) | PL185723B1 (es) |
| RU (1) | RU2158264C2 (es) |
| SI (1) | SI0871623T1 (es) |
| SK (1) | SK89598A3 (es) |
| TN (1) | TNSN96174A1 (es) |
| TR (1) | TR199801268T2 (es) |
| TW (1) | TW472054B (es) |
| UY (1) | UY24429A1 (es) |
| WO (1) | WO1997025322A1 (es) |
| YU (1) | YU71496A (es) |
| ZA (1) | ZA9747B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9714129D0 (en) * | 1997-07-04 | 1997-09-10 | Pfizer Ltd | Azetidines |
| AU1089599A (en) * | 1997-10-15 | 1999-05-03 | Coelacanth Chemical Corporation | Synthesis of azetidine derivatives |
| ES2243012T3 (es) * | 1997-12-04 | 2005-11-16 | Sankyo Company Limited | Derivados heterociclicos aliciclicos acilados. |
| GB9821898D0 (en) * | 1998-10-08 | 1998-12-02 | Pfizer Ltd | Heterocycles |
| WO2001095904A1 (en) * | 2000-06-12 | 2001-12-20 | University Of Rochester | Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist |
| US6642226B2 (en) * | 2001-02-06 | 2003-11-04 | Hoffman-La Roche Inc. | Substituted phenyl-piperidine methanone compounds |
| GB0130261D0 (en) * | 2001-12-18 | 2002-02-06 | Pfizer Ltd | Lactams as tachykinin antagonists |
| PL373410A1 (en) * | 2002-02-01 | 2005-08-22 | F.Hoffman-La Roche Ag | Substituted indoles as alpha-1 agonists |
| US7674783B2 (en) * | 2002-11-22 | 2010-03-09 | Dimera Inc. | Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease |
| CA2509406C (en) * | 2002-12-23 | 2012-07-03 | Janssen Pharmaceutica N.V. | Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
| TW200508221A (en) | 2003-06-13 | 2005-03-01 | Astrazeneca Ab | New azetidine compounds |
| EP1498123A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Emulsifying systems containing azetidine derivatives |
| WO2006012226A2 (en) | 2004-06-24 | 2006-02-02 | Incyte Corporation | N-substituted piperidines and their use as pharmaceuticals |
| US20060009491A1 (en) * | 2004-06-24 | 2006-01-12 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| NZ556628A (en) | 2005-03-08 | 2009-09-25 | Janssen Pharmaceutica Nv | Diaza-spiro-[4.4]-nonane derivatives as neurokinin (NK1) antagonists |
| AR057828A1 (es) | 2005-09-29 | 2007-12-19 | Astrazeneca Ab | Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica |
| US8106208B2 (en) | 2006-05-18 | 2012-01-31 | Albireo Ab | Benzamide compounds that act as NK receptor antagonists |
| US8093268B2 (en) | 2007-01-24 | 2012-01-10 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-) |
| RU2402546C2 (ru) * | 2008-11-20 | 2010-10-27 | Федеральное государственное учреждение "27 Научный центр Министерства Обороны Российской Федерации" | Способ получения метил 4-[(3,4-дихлорфенил)ацетил]-3-[(1-пирролидинил)метил]-1-пиперазинкарбоксилата |
| TW201026666A (en) * | 2008-12-16 | 2010-07-16 | Astrazeneca Ab | Quaternary piperidine derivatives and uses thereof |
| AU2010239188B2 (en) * | 2009-04-22 | 2016-03-31 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4226998A (en) * | 1974-09-26 | 1980-10-07 | Ciba-Geigy Corporation | 1-Benzothiepin-4-carboxamides |
| GB1600880A (en) * | 1978-05-23 | 1981-10-21 | Lilly Industries Ltd | Pharmaceutical compositions comprising hydantoin derivatives |
| SU1032752A1 (ru) * | 1981-08-14 | 1990-11-07 | Институт биохимии АН ЛитССР | Калиева соль 4-(пиперидиназо)-N-ацетилбензолсульфамида, обладающа противовоспалительной активностью |
| SE8904298D0 (sv) * | 1989-12-21 | 1989-12-21 | Astra Ab | New compounds |
| IL99320A (en) * | 1990-09-05 | 1995-07-31 | Sanofi Sa | Arylalkylamines, their preparation and pharmaceutical compositions containing them |
| FR2676055B1 (fr) | 1991-05-03 | 1993-09-03 | Sanofi Elf | Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| WO1994026735A1 (en) * | 1993-05-06 | 1994-11-24 | Merrell Dow Pharmaceuticals Inc. | Substituted pyrrolidin-3-yl-alkyl-piperidines useful as tachykinin antagonists |
| GB9315808D0 (en) * | 1993-07-30 | 1993-09-15 | Merck Sharp & Dohme | Therapeutic agents |
| JPH09507500A (ja) * | 1994-01-13 | 1997-07-29 | メルク シヤープ エンド ドーム リミテツド | ｇｅｍ二置換アザシクロ系のタキキニン拮抗薬 |
| FR2719311B1 (fr) * | 1994-03-18 | 1998-06-26 | Sanofi Sa | Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic. |
| FR2717804B1 (fr) | 1994-03-25 | 1996-06-21 | Sanofi Sa | Sels de composés hétéroaromatiques azotés substitués, procédé pour leur préparation et compositions pharmaceutiques en contenant. |
| TW432061B (en) | 1994-08-09 | 2001-05-01 | Pfizer Res & Dev | Lactams |
| WO1997022604A1 (en) | 1995-12-20 | 1997-06-26 | Hoechst Marion Roussel, Inc. | Novel substituted 4-(1h-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases |
| GB9601202D0 (en) * | 1996-01-22 | 1996-03-20 | Pfizer Ltd | Piperidones |
| GB9812037D0 (en) * | 1998-06-04 | 1998-07-29 | Pfizer Ltd | Piperidones |
| GB9821898D0 (en) * | 1998-10-08 | 1998-12-02 | Pfizer Ltd | Heterocycles |
-
1996
- 1996-01-05 GB GBGB9600235.7A patent/GB9600235D0/en active Pending
- 1996-12-06 TW TW085115107A patent/TW472054B/zh not_active IP Right Cessation
- 1996-12-09 DK DK96943119T patent/DK0871623T3/da active
- 1996-12-09 PL PL96327665A patent/PL185723B1/pl not_active IP Right Cessation
- 1996-12-09 RU RU98114667/04A patent/RU2158264C2/ru not_active IP Right Cessation
- 1996-12-09 DE DE69626220T patent/DE69626220T2/de not_active Expired - Fee Related
- 1996-12-09 ES ES96943119T patent/ES2190486T3/es not_active Expired - Lifetime
- 1996-12-09 SI SI9630590T patent/SI0871623T1/xx unknown
- 1996-12-09 CA CA002237189A patent/CA2237189C/en not_active Expired - Fee Related
- 1996-12-09 TR TR1998/01268T patent/TR199801268T2/xx unknown
- 1996-12-09 SK SK895-98A patent/SK89598A3/sk unknown
- 1996-12-09 IL IL12430996A patent/IL124309A/en not_active IP Right Cessation
- 1996-12-09 WO PCT/EP1996/005613 patent/WO1997025322A1/en not_active Ceased
- 1996-12-09 IL IL14532496A patent/IL145324A0/xx unknown
- 1996-12-09 HU HU9903590A patent/HUP9903590A3/hu unknown
- 1996-12-09 EP EP96943119A patent/EP0871623B1/en not_active Expired - Lifetime
- 1996-12-09 US US09/297,736 patent/US6242438B1/en not_active Expired - Fee Related
- 1996-12-09 KR KR1019980705159A patent/KR100275402B1/ko not_active Expired - Fee Related
- 1996-12-09 BR BR9612412A patent/BR9612412A/pt not_active Application Discontinuation
- 1996-12-09 JP JP09520769A patent/JP3123611B2/ja not_active Expired - Fee Related
- 1996-12-09 NZ NZ324712A patent/NZ324712A/xx unknown
- 1996-12-09 AT AT96943119T patent/ATE232526T1/de not_active IP Right Cessation
- 1996-12-09 CZ CZ982093A patent/CZ209398A3/cs unknown
- 1996-12-09 AU AU11950/97A patent/AU708282B2/en not_active Ceased
- 1996-12-19 AP APAP/P/1996/000901A patent/AP709A/en active
- 1996-12-27 PE PE1996000960A patent/PE29798A1/es not_active Application Discontinuation
- 1996-12-31 YU YU71496A patent/YU71496A/sr unknown
- 1996-12-31 DZ DZ960200A patent/DZ2155A1/fr active
- 1996-12-31 TN TNTNSN96174A patent/TNSN96174A1/fr unknown
- 1996-12-31 MA MA24446A patent/MA26417A1/fr unknown
-
1997
- 1997-01-02 AR ARP970100003A patent/AR005338A1/es unknown
- 1997-01-02 AR ARP970100004A patent/AR005339A1/es unknown
- 1997-01-03 ZA ZA9747A patent/ZA9747B/xx unknown
- 1997-01-03 UY UY24429A patent/UY24429A1/es not_active Application Discontinuation
- 1997-01-03 HR HR9600235.7A patent/HRP970006A2/xx not_active Application Discontinuation
- 1997-01-07 CO CO97000263A patent/CO4750815A1/es unknown
-
1998
- 1998-05-28 IS IS4760A patent/IS1876B/is unknown
- 1998-05-29 OA OA9800066A patent/OA10863A/en unknown
- 1998-06-09 NO NO19982651A patent/NO311838B1/no unknown
- 1998-06-30 BG BG102589A patent/BG102589A/xx unknown
-
2000
- 2000-05-10 JP JP2000136658A patent/JP3254205B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200200942A1 (ru) | Фармацевтические композиции, содержащие производные 3-аминоазетидина, новые производные и способ их получения | |
| AR011623A1 (es) | Compuestos de sulfonamidas, procedimiento para prepararlos y composiciones farmaceuticas para potenciar las funciones de los glutamatoreceptores enmamiferos. | |
| AR069326A1 (es) | Derivados bis-(sulfonilamino), proceso de preparacion, composiciones farmaceuticas que los contienen y su uso en terapia. | |
| ATE231488T1 (de) | Harnstoffderivate und ihre anwendung als integrin-inhibitoren | |
| AR007077A1 (es) | Derivados tetrahidroisoquinolina, un procedimiento para su preparacion, una composicion farmaceutica que los contiene, el uso de los mismos parala fabricacion de un medicamento | |
| HRP20000896B1 (en) | Adenosine derivatives | |
| EA199900866A1 (ru) | Пиразолопиримидиноны, которые ингибируют циклический гуанозин-3',5'-монофосфат-фосфодиэстеразу типа 5 (cgmp pde5), для лечения сексуального расстройства | |
| AR058546A1 (es) | Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1 | |
| AR019427A1 (es) | Compuestos heterociclicos como inhibidores de enzimas de rotamasa, procedimiento para su preparacion, su uso para la preparacion de medicamentos, composiciones farmaceuticas y compuestos intermediarios utiles para su preparacion | |
| PE20020566A1 (es) | DERIVADOS DE FENILACETAMIDO-PIRAZOLES COMO INHIBIDORES DE LA cdk/CICLINA QUINASA | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| AR021354A1 (es) | Procedimiento para la preparacion de un compuesto derivado de quinolina y un procedimiento para preparar una composicion farmaceutica | |
| AR012181A1 (es) | Un derivado de pirimidina, procedimientos para prepararlo, una composicion farmaceutica que lo comprende, y un compuesto util como intermediario parapreparar dicho derivado de pirimidina. | |
| ES2039242T3 (es) | Un procedimiento para la preparacion de nuevos derivados de piperidina. | |
| BR9307580A (pt) | Compostos processo para a preparação dos mesmos composições farmacêuticas uso de um composto e processo de tratamento de um mamífero que inclui o ser humano | |
| NO883587L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive indolderivater. | |
| NO995711L (no) | Kinolin-4-karboksamid-derivater som NK-2 og NK-3- reseptorantagonister | |
| AR015964A1 (es) | Compuestos de isoquinolina, su uso, procedimiento para tratar una afeccion, procedimiento de preparacion del compuesto, composicion farmaceutica que locontiene y compuesto util en dicho procedimiento | |
| ATE276257T1 (de) | Pyrazinonderivate | |
| AR008168A1 (es) | Compuestos etilamino arilamida aril substituidos de pirrolidinilo y pirrolinilo, composicion farmaceutica que lo contiene, compuesto util para susintesis, procedimiento para su preparacion | |
| DE60131001D1 (de) | Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten | |
| TR199903310A2 (xx) | Aril karboksilik asit ve tetrazol t�revleri. | |
| AR023111A1 (es) | Derivados de sulfonamida utiles como antagonistas del receptor 5-ht7, un procedimiento para su preparacion y composicion farmaceutica que los comprenden | |
| AR018632A1 (es) | Compuestos derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene, proceso para su preparacion. | |
| AR024219A1 (es) | COMPUESTOS DE QUINOLONAS 2-(NH- U O-SUSTITUIDAS) UTILES COMO INHIBIDORES DE LA METIONIL t-RNA SINTETASA (MRS) COMPOSICIONES FARMACEUTICAS FORMULADAS CONDICHOS COMPUESTOS; PROCEDIMIENTO PARA SU PREPARACION Y USO DE DICHOS COMPUESTOS PARA PREPARAR MEDICAMENTOS PARA EL TRATAMIENTO DE INFECCIONES BACTER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |